{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"ArriVent BioPharma, Inc."},"Symbol":{"label":"Symbol","value":"AVBP"},"Address":{"label":"Address","value":"18 CAMPUS BLVD,SUITE 100, NEWTOWN SQUARE, Pennsylvania, 19073-3269, United States"},"Phone":{"label":"Phone","value":"240-780-6356"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc."},"CompanyUrl":{"label":"Company Url","value":"https://arrivent.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Robin LaChapelle","title":"Chief Operating Officer"},{"name":"Stuart Lutzker","title":"Director, President-Research & Development"},{"name":"Yang Wang","title":"Chief Technology Officer"},{"name":"Zheng Bin Yao","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}